Hisamitsu Of Japan Sees 46 Percent Profit Increase By Early 2014
This article was originally published in PharmAsia News
Executive Summary
Japan's Hisamitsu Pharmaceutical has mapped out a business plan it says should triple the company's stock dividends by February 2014. Hisamitsu credits its recent acquisition of U.S. drug maker Noven Pharmaceutical. That purchase, Hisamitsu said, helped drive up earnings, and it now expects a net profit by the end of fiscal 2013 that is anticipated to be 46 percent higher than projected for fiscal 2008. (Click here for more - a subscription may be required
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.